More highlights from AAP San Diego!

The FDA has approved lutetium Lu 177 dotatate for pediatric patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.

Treatment with intravenous iron therapy proves more efficacious than oral or no iron therapy in improving hemoglobin in pediatric patients admitted with IBD and IDA.

Medicaid registry data show parents and guardians whose children have been referred to CPS are more than 3-fold likely to have a substance use disorder.